Search Results - "Bot, B. M."

Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes by Ho, T.H., Serie, D.J., Parasramka, M., Cheville, J.C., Bot, B.M., Tan, W., Wang, L., Joseph, R.W., Hilton, T., Leibovich, B.C., Parker, A.S., Eckel-Passow, J.E.

“…The majority of renal cell carcinoma (RCC) studies analyze primary tumors, and the corresponding results are extrapolated to metastatic RCC tumors. However, it…”
Get full text

Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database by Shi, Q., Hubbard, J. M., Yothers, G. A., Andre, T., Saltz, L., Francini, G., Bot, B. M., Twelves, C., Buyse, M. E., Grothey, A., Sargent, D. J.

“…Abstract only…”
Get full text

GCC expression in lymph nodes (LNs) as a significant determinant of recurrence in stage II colon cancer (CC) patients (pts) by Sargent, D. J., Shi, Q., Bot, B. M., Resnick, M. B., Meyers, M. O., Goldar-Najafi, A., Clancy, T. E., Gill, S., Siemons, G. O., Fradet, Y.

“…Abstract only 369 Background: A multi-center prospectively specified retrospective study Validating Indicators to Associate Recurrence (VITAR) is assessing the…”
Get full text

Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib by Lafky, J. M., Bot, B. M., Morlan, B. W., Anderson, S. K., Kimlinger, T. K., Halling, T. M., Kumar, S., Reynolds, J. T., Stella, P. J., Dakhil, S. R., Loui, W. S., Alberts, S. R., Grothey, A.

“…Abstract only…”
Get full text

Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials by Blanke, C. D., Bot, B. M., Thomas, D. M., Bleyer, A., Kohne, C., Seymour, M. T., De Gramont, A., Goldberg, R. M., Sargent, D. J.

“…Abstract only…”
Get full text

Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)—Findings from the ACCENT dataset by Andre, T., Shi, Q., Yothers, G. A., Bot, B. M., Haller, D. G., Van Cutsem, E., Cassidy, J., Benedetti, J., O'Connell, M., Sargent, D. J.

“…Abstract only…”
Get full text

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C by Grothey, A., Lafky, J. M., Morlan, B. W., Stella, P. J., Dakhil, S. R., Steen, P. D., Loui, W. S., Bot, B. M., Alberts, S. R., Reynolds, J. T.

“…Abstract only…”
Get full text

Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG) by Hillman, S. L., Sargent, D. J., Bot, B. M., DeMatteo, R. P., Perez, E. A., Ballman, K. V., Mandrekar, S. J.

“…Abstract only 6511 Background: In March 1998, the Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AE) to…”
Get full text

A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) by Okuno, S. H., Mahoney, M. R., Bailey, H. H., Adkins, D. R., Maples, W. J., Ettinger, D., Fitch, T. R., Bot, B. M., Erlichman, C. E.

“…Abstract only 9504 Background: CCI-779 inhibits the mammalian target of rapamycin (mTOR), a Ser/Thr kinase involved with the initiation of mRNA translation,…”
Get full text

Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial by Hillman, S. L., Mandrekar, S. J., Bot, B. M., Perez, E. A., Kugler, J. W., Adjei, A. A., Buckner, J. C., Sargent, D. J.

“…Abstract only 6006 Background: In March 1998, the Common Toxicity Criteria version 2.0 was implemented and introduced the collection and reporting of…”
Get full text

Expression of endothelin 2 and localized clear cell renal cell carcinoma by Bot, Brian M., BS, Eckel-Passow, Jeanette E., PhD, LeGrand, Shauna N., BS, Hilton, Tracy, BS, Cheville, John C., MD, Igel, Todd, MD, Parker, Alexander S., PhD

“…Summary Despite the rising incidence of clear cell renal cell carcinoma, the molecular events that support its development and progression remain unclear…”
Get full text